Novartis AG (NOT) Stock Price & News

Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by revenue in 2024. Novartis manufactures the drugs clozapine, diclofenac, carbamazepine, valsartan, imatinib mesylate, cyclosporine, letrozole, methylphenidate, terbinafine, deferasirox, and others. Novartis was formed in 1996 by the merger of Ciba-Geigy and Sandoz. It was considered the largest corporate merger in history during that time. The pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. The name Novartis was based on the Latin terms, novae artes. After the merger, other Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Wikipedia

About Novartis AG

CEOVasant Narasimhan

Employees75.3K

FoundedMar 7, 1996

HeadquartersBasel, Basel City, Switzerland

SectorPharmaceutical industry

Websitenovartis.com

All values in USD	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	14.36B	13.86B	13.52B	14.95B
Cost of goods sold	3.54B	3.54B	3.44B	3.68B
Cost of revenue	3.54B	3.54B	3.44B	3.68B
Research and development expenses	2.86B	2.84B	2.78B	2.74B
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	3.30B	3.44B	3.14B	3.23B
Operating expense	6.24B	6.46B	5.96B	6.10B
Total operating expenses	9.77B	10.00B	9.40B	9.78B
Operating income	4.58B	3.86B	4.12B	5.18B
Other non operating income	-7.00M	-130.00M	4.00M	19.00M
EBT including unusual items	4.20B	3.22B	3.84B	4.27B
EBT excluding unusual items	4.29B	3.49B	3.78B	4.73B
Income tax expense	266.00M	814.00M	683.00M	1.01B
Effective tax rate	6.34%	25.30%	17.79%	23.71%
Other operating expenses	70.00M	190.00M	42.00M	127.00M
Net income	3.93B	2.41B	3.16B	3.26B
Net profit margin	27.36%	17.38%	23.34%	21.83%
Earnings per share	2.25	2.03	1.99	2.41
Interest and investment income	-	373.00M	-	-
Interest expense	-281.00M	-304.00M	-343.00M	-462.00M
Net interest expenses	-281.00M	69.00M	-343.00M	-462.00M
Depreciation and amortization charges	-	-	-	-
EBITDA	5.78B	4.96B	5.24B	6.30B
Gain or loss from assets sale	81.00M	80.00M	-159.00M	-247.00M

Ask anything